Gemzar approved for breast cancer
Lilly's Gemzar approved for use in combination with Bristol-Myers Squibb's Taxol for first-line treatment of metastatic breast cancer May 19. Clinical studies included in 1labeling show improvement in time to disease progression of 2.3 months over paclitaxel alone (5.2 versus 2.9 months). Overall response rate was 40.8% versus 22.1% for paclitaxel alone. Gemzar is already indicated for first-line non-small cell lung and pancreatic cancer...
You may also be interested in...
Japanese major links with new partners in European consortium to progress first-in-class molecule for multiple hematological malignancies.
Executive order calls for short-term and long-term study, broad consultation, coordination with allies.
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.